Medical · Ongoing coverage · 1,141 words

Cannabis and Cancer: Symptom Relief, Evidence, and Treatment Limits

This hub explains what is and is not known about cannabis in cancer care. It covers the evidence for managing symptoms such as chemotherapy-induced nausea, pain, poor appetite, anxiety, and sleep disturbance, and the FDA-approved cannabinoid medicines used for some of these. It also separates symptom relief from the unproven claim that cannabis cures cancer, and addresses drug interactions, risks, and medical marijuana access by state. It includes recent survey research, such as a University of Kentucky study of 237 patients receiving radiation, in which most respondents reported relief. Patients should discuss any cannabis use with their oncology team.

Last updated October 12, 2026 · 0 updates since publication
A person looking at a 'Fight Cancer' sign symbolizes cancer awareness.
Cannabis is used mainly to ease cancer-related symptoms such as nausea, pain, poor appetite, anxiety, and sleep problems, not to cure the disease. Patient surveys, including a University of Kentucky study of 237 adults receiving radiation, report that most users find relief. Evidence that cannabis shrinks tumors in humans remains insufficient.

Executive Summary

Cannabis has solid-but-narrow evidence as a symptom-management tool for cancer patients and no clinical evidence that it cures or shrinks tumors in people. That split between supportive care and anti-cancer treatment is the single most important fact on this page.

On September 28, 2026, Marijuana Moment reported on a University of Kentucky study that surveyed 237 adults receiving radiation therapy. According to the report, medical cannabis is "commonly" used for pain, nausea, anxiety, depression, poor appetite and sleep disturbance. About 80 percent of respondents said it provided relief and improved quality of life. The finding fits a decade of patient-reported data, but surveys cannot prove cause and effect.

The regulatory picture is lopsided. Cannabis remains a Schedule I substance under 21 U.S.C. § 812, while roughly 40 states and the District of Columbia run medical programs that list cancer or chemotherapy side effects as qualifying conditions. The FDA has approved cannabinoid drugs only for narrow uses: dronabinol and nabilone for chemotherapy-induced nausea and vomiting (CINV), and dronabinol for AIDS-related anorexia. It has not approved cannabis to treat cancer itself.

For patients, the practical questions are which symptoms respond, which products and doses are reasonable, and what interactions with cancer drugs to watch for. For operators and investors, oncology patients are a durable, high-need medical segment whose economics depend on rescheduling, 280E relief and state program design.

Why This Matters

Cancer is the largest single driver of demand for symptom-focused medical cannabis, and the evidence gap between patient experience and clinical proof shapes policy, product design and liability.

The American Cancer Society projected about 2.04 million new U.S. cancer diagnoses and roughly 618,000 deaths in 2025. Many of those patients endure treatment-related symptoms that standard care controls imperfectly: neuropathic pain, nausea that breaks through antiemetics, cachexia, insomnia and anxiety. Radiation patients, the population in the Kentucky study, add mucositis, fatigue and skin injury to that list.

Who has a stake

  • Patients and caregivers pay out of pocket. Health insurance does not cover state-licensed medical cannabis, so cost, access and product consistency fall directly on the household.
  • Oncologists and palliative-care teams field questions they are often not trained to answer. A 2018 survey of oncologists published by ASCO researchers found most had discussed cannabis with patients, but only a minority felt sufficiently informed to recommend it.
  • State regulators decide qualifying conditions, product forms and dosing guidance.
  • Licensed operators, including multi-state operators (MSOs), compete for medical patients as adult-use markets mature and prices compress.
  • Federal agencies, chiefly the DEA, FDA and NIH, control research access and drug-approval pathways.

The dollar and patient lens

A patient on active treatment may spend hundreds of dollars a month on oils, capsules, tinctures or flower. Because federal law blocks insurance reimbursement and FDA review of whole-plant products, patients make dosing decisions with little standardized guidance. That is the central failure the Kentucky survey illustrates: patients report benefit at scale while clinicians lack trial-grade evidence to guide them.

Background and History

Cannabis moved from 19th-century pharmacopeia to Schedule I prohibition and back into oncology supportive care through patient demand, state ballot measures and a handful of FDA-approved cannabinoid drugs.

Before prohibition: cannabis in the pharmacopeia

Cannabis extracts appeared in the United States Pharmacopeia in the 19th century and were sold for pain, nausea and appetite. The Marihuana Tax Act of 1937 effectively ended mainstream medical use, and cannabis was dropped from the pharmacopeia in 1942.

1970: the Controlled Substances Act

Congress placed marijuana in Schedule I of the Controlled Substances Act in 1970, defining it as having high abuse potential and no accepted medical use. That classification, codified at 21 U.S.C. § 812, still governs federal law and still limits clinical research to a narrow set of registered suppliers and protocols.

1964 to 1985: THC isolated, synthetic cannabinoids approved

Israeli chemist Raphael Mechoulam and colleagues isolated THC in 1964. The finding made pharmaceutical development possible. In 1985 the FDA approved dronabinol (Marinol) and nabilone (Cesamet) for CINV in patients who had not responded to conventional antiemetics. The FDA added dronabinol for AIDS-related anorexia in 1992. A liquid dronabinol formulation, Syndros, followed in 2016. Oncology therefore has the longest regulatory history with cannabinoid medicine of any specialty.

1996: California opens the state medical era

Voters in California passed Proposition 215 in 1996, the first state medical cannabis law. Cancer patients were central to the campaign, and the law's language named cancer among the qualifying illnesses. Other states followed over the next 25 years through ballot measures and legislation.

1998 to 2006: first signals on tumor biology

Laboratory work in the late 1990s and 2000s showed that cannabinoids could slow tumor growth or trigger cell death in cell cultures and animal models. In 2006, a Spanish research group led by Manuel Guzmán published a pilot trial in the British Journal of Cancer in which nine patients with recurrent glioblastoma received intratumoral THC. The study established safety and generated hypotheses. It was small, uncontrolled and did not demonstrate that cannabinoids extend survival.

2014: the congressional appropriations rider

Congress adopted the Rohrabacher-Farr amendment (later Joyce-Blumenauer) in 2014, barring the Justice Department from using funds to interfere with state medical cannabis programs. Congress has renewed it each year through spending bills. It protects state-compliant patients and operators from federal prosecution funding, but it does not change the underlying Schedule I status.

2017: the National Academies review

The National Academies of Sciences, Engineering, and Medicine published its landmark review in January 2017. It found conclusive or substantial evidence that cannabis is effective for chronic pain in adults and that oral cannabinoids are effective antiemetics for CINV. It found insufficient evidence for appetite and weight loss in cancer and for effects on cancer incidence. That review remains the benchmark for what the evidence supports.

2018 to 2020: Epidiolex and the CBD split

The FDA approved Epidiolex, a purified CBD solution, in June 2018 for two severe childhood epilepsy syndromes. The approval proved that the FDA pathway can work for plant-derived cannabinoids. It also pushed regulators and clinicians to treat CBD, THC and minor cannabinoids as distinct drugs with distinct risk profiles.

2023 to 2026: rescheduling and survey evidence

In August 2023, HHS recommended moving marijuana to Schedule III. In May 2024, the DOJ and DEA published a notice of proposed rulemaking (NPRM) to do so. An administrative law judge (ALJ) hearing was scheduled for early 2025 and then stayed amid procedural disputes. According to reporting at the time, President Trump signed an executive order in December 2025 directing the attorney general to expedite rescheduling. Readers should check the Federal Register for the current status.

Meanwhile, state-level survey research kept accumulating. The Kentucky study, published in September 2026, adds a radiation-oncology data point at a time when Kentucky's own medical program is new.

Key

Frequently asked questions

Can cannabis cure cancer?

No. There is no clinical evidence that cannabis or cannabinoids cure cancer in humans. Laboratory and animal studies have shown some cannabinoids may slow tumor growth or trigger cancer cell death, but those results have not been confirmed in rigorous human trials. The National Cancer Institute states that cannabis should not replace standard treatment such as surgery, chemotherapy, radiation, or immunotherapy.

What cancer symptoms can cannabis help with?

Patients most commonly use cannabis for pain, nausea and vomiting, loss of appetite, anxiety, depression, and sleep disturbance. Evidence is strongest for chemotherapy-induced nausea and vomiting and for some chronic pain. Evidence for appetite, mood, and sleep is more mixed, and results vary with the product, dose, and individual patient.

What did the University of Kentucky study find?

Researchers at the University of Kentucky surveyed 237 adults receiving radiation therapy for cancer. As reported by Marijuana Moment in September 2026, medical cannabis was commonly used for symptoms like pain, nausea, anxiety, depression, poor appetite, and sleep problems, and about 80 percent of users reported relief and improved quality of life. Because it is a self-reported survey, it cannot prove cause and effect.

Are there FDA-approved cannabis-based drugs for cancer patients?

Yes, for symptoms. The FDA has approved dronabinol (Marinol, Syndros) and nabilone (Cesamet) for chemotherapy-induced nausea and vomiting. Dronabinol is also approved for AIDS-related anorexia and weight loss. These are synthetic cannabinoids. The FDA has not approved cannabis or cannabinoids as a treatment for cancer itself.

Is CBD or THC better for cancer symptoms?

It depends on the symptom. THC is the cannabinoid most associated with nausea relief and appetite stimulation, but it can cause intoxication, anxiety, and dizziness. CBD is non-intoxicating and is often used for anxiety and inflammation, though human cancer-specific evidence is limited. Many patients use combined products, and dosing should be guided by a clinician.

Can cannabis interact with chemotherapy or other cancer drugs?

Possibly. THC and CBD are processed by liver enzymes, including CYP3A4 and CYP2C19, that also metabolize some cancer drugs. This could raise or lower drug levels. Cannabis can also add to the sedation caused by opioids and other medications. Patients should tell their oncology team about all cannabis use before and during treatment.

What are the risks of using cannabis during cancer treatment?

Risks include drowsiness, dizziness, anxiety, impaired thinking, increased heart rate, and falls. Smoking or vaping can irritate the lungs, which is a particular concern for patients with compromised immunity. Edibles can have delayed, unpredictable effects. Some research also questions whether cannabis affects immunotherapy outcomes, so clinicians advise caution and monitoring.

Does cannabis help with cancer pain?

It may help some patients. Reviews of cannabinoids for cancer pain show mixed results, with modest benefit in some trials and no clear advantage over placebo in others. Cannabis is generally considered an adjunct rather than a replacement for standard pain management, and some patients use it to reduce reliance on other pain medicines under medical supervision.

Can cancer patients get medical marijuana?

In states with medical cannabis programs, cancer is a qualifying condition almost everywhere. Patients typically need a recommendation from a licensed clinician and a state registry card, though rules vary. Cannabis remains federally illegal under the Controlled Substances Act, so hospitals and cancer centers may restrict its use or storage on site.

How should a patient talk to their oncologist about cannabis?

Be open about what you use, how often, in what form, and why. Bring product labels showing THC and CBD content. Ask about interactions with your treatment, the right dose and timing, and whether it affects your symptoms or care plan. Do not stop or delay prescribed cancer treatment in favor of cannabis.

cancermedical-cannabischemotherapy-nauseacancer-paincannabinoidsquality-of-life
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.